Quarterly report · Q3
4078.TEDINET S100THLQ
Period2023-04-01 → 2023-12-31
Filed2024-05-27
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Amends S100ST22.
Key figures · 33
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥60.8bn | 2023-04-01 → 2023-12-31 | Cons. | Net sales |
| Revenue | ¥83.9bn | 2022-04-01 → 2023-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥63.8bn | 2022-04-01 → 2022-12-31 | Cons. | Net sales |
| Operating income | ¥1.7bn | 2023-04-01 → 2023-12-31 | Cons. | Operating income |
| Operating income | ¥4.2bn | 2022-04-01 → 2022-12-31 | Cons. | Operating income |
| Ordinary income | ¥1.8bn | 2023-04-01 → 2023-12-31 | Cons. | Ordinary income |
| Ordinary income | ¥4.9bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥4.7bn | 2022-04-01 → 2022-12-31 | Cons. | Ordinary income |
| Profit before tax | −¥4.5bn | 2023-04-01 → 2023-12-31 | Cons. | Income before income taxes |
| Profit before tax | ¥5.0bn | 2022-04-01 → 2022-12-31 | Cons. | Income before income taxes |
| Net income (owners) | −¥7.5bn | 2023-04-01 → 2023-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥2.3bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥3.4bn | 2022-04-01 → 2022-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | −¥7.2bn | 2023-04-01 → 2023-12-31 | Cons. | Profit loss |
| Net income | ¥3.6bn | 2022-04-01 → 2022-12-31 | Cons. | Profit loss |
| Total assets | ¥123.7bn | at 2023-12-31 | Cons. | Assets |
| Total assets | ¥128.0bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥131.3bn | at 2022-12-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥48.9bn | at 2023-12-31 | Cons. | Liabilities |
| Total liabilities | ¥43.3bn | at 2023-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥74.7bn | at 2023-12-31 | Cons. | Net assets |
| Net assets / equity | ¥84.7bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥85.7bn | at 2022-12-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥13.6bn | at 2023-12-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥12.4bn | at 2023-03-31 | Cons. | Cash and deposits |
| EPS (basic) | ¥-460.96 | 2023-04-01 → 2023-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-335.43 | 2023-10-01 → 2023-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥144.85 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥207.79 | 2022-04-01 → 2022-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥30.31 | 2022-10-01 → 2022-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 59.5% | at 2023-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 62.9% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 62.0% | at 2022-12-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 30
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2023-12-31 | −¥907m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2023-12-31 | −¥907m |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-12-31 | −¥1.7bn |
| jpcrp040300-q3r_E00780-000Chemicalreportable segment | revenue | 2023-04-01 → 2023-12-31 | ¥55.1bn |
| jpcrp040300-q3r_E00780-000Chemicalreportable segment | revenue external | 2023-04-01 → 2023-12-31 | ¥54.4bn |
| jpcrp040300-q3r_E00780-000Chemicalreportable segment | revenue intersegment | 2023-04-01 → 2023-12-31 | ¥726m |
| jpcrp040300-q3r_E00780-000Chemicalreportable segment | segment profit | 2023-04-01 → 2023-12-31 | ¥3.1bn |
| jpcrp040300-q3r_E00780-000Medicine And Health Carereportable segment | revenue | 2023-04-01 → 2023-12-31 | ¥6.5bn |
| jpcrp040300-q3r_E00780-000Medicine And Health Carereportable segment | revenue external | 2023-04-01 → 2023-12-31 | ¥6.4bn |
| jpcrp040300-q3r_E00780-000Medicine And Health Carereportable segment | revenue intersegment | 2023-04-01 → 2023-12-31 | ¥181m |
| jpcrp040300-q3r_E00780-000Medicine And Health Carereportable segment | segment profit | 2023-04-01 → 2023-12-31 | ¥260m |
| —segment total | revenue | 2023-04-01 → 2023-12-31 | ¥61.7bn |
| —segment total | revenue external | 2023-04-01 → 2023-12-31 | ¥60.8bn |
| —segment total | revenue intersegment | 2023-04-01 → 2023-12-31 | ¥907m |
| —segment total | segment profit | 2023-04-01 → 2023-12-31 | ¥3.4bn |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-12-31 | −¥808m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-12-31 | −¥808m |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-12-31 | −¥1.7bn |
| jpcrp040300-q3r_E00780-000Chemicalreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥58.1bn |
| jpcrp040300-q3r_E00780-000Chemicalreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥57.5bn |
| jpcrp040300-q3r_E00780-000Chemicalreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥575m |
| jpcrp040300-q3r_E00780-000Chemicalreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥5.5bn |
| jpcrp040300-q3r_E00780-000Medicine And Health Carereportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥6.5bn |
| jpcrp040300-q3r_E00780-000Medicine And Health Carereportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥6.3bn |
| jpcrp040300-q3r_E00780-000Medicine And Health Carereportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥233m |
| jpcrp040300-q3r_E00780-000Medicine And Health Carereportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥394m |
| —segment total | revenue | 2022-04-01 → 2022-12-31 | ¥64.6bn |
| —segment total | revenue external | 2022-04-01 → 2022-12-31 | ¥63.8bn |
| —segment total | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥808m |
| —segment total | segment profit | 2022-04-01 → 2022-12-31 | ¥5.9bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 376
| Item | Context | Value | Unit |
|---|---|---|---|
| Transactions with other segments | Prior1YTDDuration_ReconcilingItemsMember | -808000000 | JPY |
| Transactions with other segments | Prior1YTDDuration | － | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q3r_E00780-000ChemicalReportableSegmentsMember | 58065000000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q3r_E00780-000MedicineAndHealthCareReportableSegmentsMember | 6502000000 | JPY |
| Net sales | Prior1YTDDuration_ReportableSegmentsMember | 64568000000 | JPY |
| Net sales | Prior1YTDDuration_ReconcilingItemsMember | -808000000 | JPY |
| Net sales | Prior1YTDDuration | 63759000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q3r_E00780-000ChemicalReportableSegmentsMember | 5477000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q3r_E00780-000MedicineAndHealthCareReportableSegmentsMember | 394000000 | JPY |
| Operating income | Prior1YTDDuration_ReportableSegmentsMember | 5871000000 | JPY |
| Operating income | Prior1YTDDuration_ReconcilingItemsMember | -1689000000 | JPY |
| Operating income | Prior1YTDDuration | 4182000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q3r_E00780-000ChemicalReportableSegmentsMember | 54401000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q3r_E00780-000MedicineAndHealthCareReportableSegmentsMember | 6353000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_ReportableSegmentsMember | 60755000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | CurrentYTDDuration | 60755000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q3r_E00780-000ChemicalReportableSegmentsMember | 726000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q3r_E00780-000MedicineAndHealthCareReportableSegmentsMember | 181000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_ReportableSegmentsMember | 907000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_ReconcilingItemsMember | -907000000 | JPY |
| Transactions with other segments | CurrentYTDDuration | － | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q3r_E00780-000ChemicalReportableSegmentsMember | 55128000000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q3r_E00780-000MedicineAndHealthCareReportableSegmentsMember | 6534000000 | JPY |
| Net sales | CurrentYTDDuration_ReportableSegmentsMember | 61662000000 | JPY |
| Net sales | CurrentYTDDuration_ReconcilingItemsMember | -907000000 | JPY |
| Net sales | CurrentYTDDuration | 60755000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q3r_E00780-000ChemicalReportableSegmentsMember | 3135000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q3r_E00780-000MedicineAndHealthCareReportableSegmentsMember | 260000000 | JPY |
| Operating income | CurrentYTDDuration_ReportableSegmentsMember | 3396000000 | JPY |
| Operating income | CurrentYTDDuration_ReconcilingItemsMember | -1691000000 | JPY |
| Operating income | CurrentYTDDuration | 1705000000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)四半期報告書（2024年５月27日付け訂正報告書の添付インラインXBRL） | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条の４の７第１項 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)関東財務局長 | |
| Filing date cover page | FilingDateInstant | 2024-02-09 | |
| Quarterly accounting period cover page | FilingDateInstant | Original text (Japanese)第129期第３四半期（自 2023年10月１日 至 2023年12月31日） | |
| Company name cover page | FilingDateInstant | Original text (Japanese)堺化学工業株式会社 | |
| Company name in english cover page | FilingDateInstant | SAKAI CHEMICAL INDUSTRY CO., LTD. | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)代表取締役社長 矢倉 敏行 | |
| Address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)堺市堺区戎島町５丁２番地 | |
| Telephone number address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)０７２（２２３）４１１１（代表） | |
| Name of contact person address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)取締役経理部長 服部 浩之 | |
| Nearest place of contact cover page | FilingDateInstant | Original text (Japanese)東京都千代田区岩本町２丁目３番３号 ザイマックス岩本町ビル内 | |
| Telephone number nearest place of contact cover page | FilingDateInstant | Original text (Japanese)０３（５８２３）３７２１（代表） | |
| Name of contact person nearest place of contact cover page | FilingDateInstant | Original text (Japanese)東京事務所長 後藤 幸辰 | |
| Place for public inspection cover page (text) | FilingDateInstant | Text · Plus | |
| Edinet code | FilingDateInstant | E00780 | |
| Fund code | FilingDateInstant | － | |
| Security code | FilingDateInstant | 40780 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |